var data={"title":"Overview of gastrointestinal peptides in health and disease","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Overview of gastrointestinal peptides in health and disease</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/contributors\" class=\"contributor contributor_credentials\">Rodger A Liddle, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/contributors\" class=\"contributor contributor_credentials\">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 23, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gastrointestinal (GI) hormones are predominantly polypeptides produced in and secreted from specialized gut endocrine cells [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/1,2\" class=\"abstract_t\">1,2</a>]. These cells produce a variety of chemical transmitters that are involved in GI motility, secretion, absorption, growth, and development. Many of the peptides in the GI tract are also found in the enteric nervous system and the central nervous system.</p><p>An overview of the synthesis, secretion, and regulation of GI peptides; their role in causing disease; and their clinical application will be discussed here. The regulation and functions of the individual GI peptides are discussed separately. (See <a href=\"topic.htm?path=physiology-of-gastrin\" class=\"medical medical_review\">&quot;Physiology of gastrin&quot;</a> and <a href=\"topic.htm?path=ghrelin\" class=\"medical medical_review\">&quot;Ghrelin&quot;</a> and <a href=\"topic.htm?path=pancreatic-polypeptide-peptide-yy-and-neuropeptide-y\" class=\"medical medical_review\">&quot;Pancreatic polypeptide, peptide YY, and neuropeptide Y&quot;</a> and <a href=\"topic.htm?path=insulin-action\" class=\"medical medical_review\">&quot;Insulin action&quot;</a> and <a href=\"topic.htm?path=physiology-of-somatostatin-and-its-analogues\" class=\"medical medical_review\">&quot;Physiology of somatostatin and its analogues&quot;</a> and <a href=\"topic.htm?path=physiology-of-cholecystokinin\" class=\"medical medical_review\">&quot;Physiology of cholecystokinin&quot;</a> and <a href=\"topic.htm?path=secretin\" class=\"medical medical_review\">&quot;Secretin&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2873712916\"><span class=\"h1\">CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gastrointestinal (GI) peptides are classified into families based on their primary structure (<a href=\"image.htm?imageKey=GAST%2F52723\" class=\"graphic graphic_table graphicRef52723 \">table 1</a>). Conservation of amino acid sequence among different GI peptides suggests a common biosynthetic origin.</p><p class=\"headingAnchor\" id=\"H2743601118\"><span class=\"h1\">SYNTHESIS AND SECRETION</span></p><p class=\"headingAnchor\" id=\"H936182783\"><span class=\"h2\">Synthesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Enteroendocrine cells producing gastrointestinal (GI) peptides are dispersed throughout the GI tract. However, specific types of cells demonstrate regional specificity (<a href=\"image.htm?imageKey=GAST%2F65917\" class=\"graphic graphic_table graphicRef65917 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/3\" class=\"abstract_t\">3</a>]. This specificity may be related to the physiologic action of the peptide and receptor location.</p><p>All GI peptides are synthesized via gene transcription of DNA into messenger RNA (mRNA) and subsequently undergo translation into precursor proteins known as preprohormones. Translation occurs on ribosomes, which are complex organelles composed of many proteins (greater than 50) and multiple large RNA molecules [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p class=\"headingAnchor\" id=\"H380218849\"><span class=\"h2\">Posttranslational processing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Preprohormones undergo intracellular processing in the rough endoplasmic reticulum and packaging in the Golgi apparatus prior to release and are then stored in secretory granules as hormones (<a href=\"image.htm?imageKey=GAST%2F50859\" class=\"graphic graphic_figure graphicRef50859 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/6\" class=\"abstract_t\">6</a>]. Some peptides undergo further modification while in the secretory granule. The amino terminal sequence of a GI preprohormone contains a signal peptide that targets it for secretion. Enzymatic cleavage of the signal peptide produces a prohormone. Signal peptide cleavage and the vast majority of peptide modifications occur in the endoplasmic reticulum. Posttranslational modification of peptide hormones is important in receptor binding, signal transduction, and consequent cell responses, all of which may affect biological activity [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/7\" class=\"abstract_t\">7</a>].</p><p>Other posttranslational modifications are specific to the particular hormone. Some undergo peptide cleavage to smaller forms (eg, somatostatin), amidation of the carboxyl terminus (eg, gastrin), and sulfation of tyrosine residues (eg, cholecystokinin [CCK]). These processing steps are usually critical for biological activity of the hormone [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/6\" class=\"abstract_t\">6</a>]. As an example, sulfated CCK is 100-fold more potent than its unsulfated form.</p><p>In addition, many hormone genes are capable of manufacturing alternatively spliced mRNAs or proteins that undergo different posttranslational processing steps (<a href=\"image.htm?imageKey=GAST%2F50859\" class=\"graphic graphic_figure graphicRef50859 \">figure 1</a> and <a href=\"image.htm?imageKey=GAST%2F58292\" class=\"graphic graphic_figure graphicRef58292 \">figure 2</a>), ultimately producing hormones of different sizes from the same gene. Gastrin and CCK exist in multiple molecular forms in blood and tissues.</p><p>The biochemical complexity of gastroenteropancreatic hormone processing is evident in the different tissues that produce these peptides. Many GI hormones are secreted from endocrine cells as well as nerves. The distinct tissue involved often determines the processing steps for production of the hormone.</p><p class=\"headingAnchor\" id=\"H579955665\"><span class=\"h2\">Secretion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many gut endocrine cells have their apical surfaces open to the intestinal lumen and contain abundant secretory granules that are concentrated along the basolateral surfaces. Because of this orientation, endocrine cells can be directly influenced by luminal contents. When endocrine cells are stimulated, peptides are secreted into the paracellular space, where they act (<a href=\"image.htm?imageKey=GAST%2F77856\" class=\"graphic graphic_figure graphicRef77856 \">figure 3</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On the same cells from which they are released (autocrine)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On neighboring cells (paracrine)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On distant cells via the blood (endocrine)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On adjacent nerves through a synaptic connection [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/8\" class=\"abstract_t\">8</a>]</p><p/><p>Although GI peptides are typically thought of as hormones, not all peptides act via the traditional endocrine pathway by which they are secreted into the blood stream and act at a distant site. Thus far, only gastrin, <a href=\"topic.htm?path=secretin-drug-information\" class=\"drug drug_general\">secretin</a>, and CCK have been proven to act as true hormones, although multiple other peptides may function in this manner (<a href=\"image.htm?imageKey=GAST%2F64495\" class=\"graphic graphic_table graphicRef64495 \">table 3</a>). Neural transmission has been demonstrated by somatostatin-producing D cells. D cells in the stomach have cellular processes that extend to neighboring gastrin-producing G cells in the antrum and inhibit gastrin release. CCK-producing I cells and peptide YY (PYY)-producing L cells also possess basal processes called neuropods that extend to epithelial cells and penetrate the lamina propria to reach subepithelial cells [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/9,10\" class=\"abstract_t\">9,10</a>]. Neuropods are comprised of neurofilaments and contain large numbers of secretory vesicles and abundant mitochondria [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/11\" class=\"abstract_t\">11</a>]. They are escorted by glia, suggesting they directly communicate with other nearby cells including neurons.</p><p class=\"headingAnchor\" id=\"H1498382458\"><span class=\"h1\">REGULATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Regulation of gastrointestinal (GI) peptide secretion is necessary for normal bowel function, including nutrient assimilation and homeostasis. All cellular proteins are regulated at the genetic level. The biochemical information that encodes for the production of proteins resides in the genome, in defined regions of specific chromosomes. Specific gene regulatory elements determine if and when a protein is produced, and the particular cell in which it will be expressed. Gut hormone gene expression is regulated according to the physiologic needs of the organism. The production of GI hormones increases when gut endocrine cells are stimulated by food, intraluminal pH, releasing factors, other hormones, or transmitters. Once a biologic response is elicited, signals may then be sent to the endocrine cell to turn off secretion. This negative feedback mechanism is common to many physiologic systems and avoids excess production and secretion of hormone. (See <a href=\"topic.htm?path=physiology-of-gastrin\" class=\"medical medical_review\">&quot;Physiology of gastrin&quot;</a> and <a href=\"topic.htm?path=ghrelin\" class=\"medical medical_review\">&quot;Ghrelin&quot;</a> and <a href=\"topic.htm?path=pancreatic-polypeptide-peptide-yy-and-neuropeptide-y\" class=\"medical medical_review\">&quot;Pancreatic polypeptide, peptide YY, and neuropeptide Y&quot;</a> and <a href=\"topic.htm?path=insulin-action\" class=\"medical medical_review\">&quot;Insulin action&quot;</a> and <a href=\"topic.htm?path=physiology-of-somatostatin-and-its-analogues\" class=\"medical medical_review\">&quot;Physiology of somatostatin and its analogues&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2901161075\"><span class=\"h1\">ASSOCIATED DISEASES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Alterations in either gastrointestinal (GI) peptide secretion or action can have deleterious effects [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/12\" class=\"abstract_t\">12</a>]. Clinically significant disease can occur due to overproduction of by GI tumors (eg, gastrinoma, VIPoma), loss of regulation (eg, medication-induced hypersecretion), and receptor signaling errors (eg, toxin-induced diarrhea).</p><p>Any enteroendocrine cell within the GI tract can serve as a nidus for hyperplasia or neoplasia [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/13\" class=\"abstract_t\">13</a>]. Although these tumors are rare, their secreted hormones often produce clinical manifestations (<a href=\"image.htm?imageKey=GAST%2F71093\" class=\"graphic graphic_table graphicRef71093 \">table 4</a>). Most gut endocrine tumors elaborate several secretory products, but one hormone usually predominates. The clinical findings are determined by the amount and type of peptide secreted. As an example, gastrinomas, the most common functional pancreatic neuroendocrine tumors, are caused by hypersecretion of gastrin and result in severe acid-related peptic disease and diarrhea. (See <a href=\"topic.htm?path=zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis&quot;</a>.)</p><p>Most peptide hormones transduce their information through G protein-coupled receptors. In certain circumstances, defects in receptor signaling or coupling can produce disease in the absence of excess hormone production. As an example, <em>Vibrio cholerae</em> toxin covalently modifies the alpha-subunit of the stimulatory G protein in enterocytes. This activates the signaling pathway and stimulates intestinal secretion, resulting in voluminous watery diarrhea [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/14\" class=\"abstract_t\">14</a>]. (See <a href=\"topic.htm?path=peptide-hormone-signal-transduction-and-regulation\" class=\"medical medical_review\">&quot;Peptide hormone signal transduction and regulation&quot;</a> and <a href=\"topic.htm?path=cholera-clinical-features-diagnosis-treatment-and-prevention\" class=\"medical medical_review\">&quot;Cholera: Clinical features, diagnosis, treatment, and prevention&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLINICAL APPLICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Understanding the physiology of gastrointestinal (GI) peptides has led to novel diagnostic and therapeutic uses (<a href=\"image.htm?imageKey=GAST%2F68963\" class=\"graphic graphic_table graphicRef68963 \">table 5</a>) [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"headingAnchor\" id=\"H1233968111\"><span class=\"h2\">Diagnostic evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several gut peptides have been used in diagnostic evaluation. As examples, radiolabeled form of the somatostatin analog <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> (111-indium pentetreotide) using somatostatin-receptor scintigraphy (OctreoScan) is used to localize neuroendocrine tumors; <a href=\"topic.htm?path=secretin-drug-information\" class=\"drug drug_general\">secretin</a> is used as an adjunct with magnetic resonance imaging (MRI) to evaluate pancreatic secretion and ductal obstruction; cholecystokinin (CCK)-stimulated cholescintigraphy is used to estimate the gallbladder ejection fraction (<a href=\"image.htm?imageKey=GAST%2F68963\" class=\"graphic graphic_table graphicRef68963 \">table 5</a>).</p><p class=\"headingAnchor\" id=\"H4096102322\"><span class=\"h2\">Therapeutic uses</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of GI peptides or their analogues or drugs targeted at specific GI hormone receptors are used clinically. Some examples of therapeutic application of GI peptides include the following (<a href=\"image.htm?imageKey=GAST%2F68963\" class=\"graphic graphic_table graphicRef68963 \">table 5</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Diarrhea</strong> &ndash; Somatostatin analogue, <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> is used for the treatment of chronic diarrhea, GI hormone-secreting tumors (particularly VIPoma), and GI tract fistulas. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;</a>.)</p><p/><p class=\"bulletIndent1\">A glucagon-like peptide-2 analog (<a href=\"topic.htm?path=teduglutide-drug-information\" class=\"drug drug_general\">teduglutide</a>) has been used to treat short bowel syndrome [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/16-19\" class=\"abstract_t\">16-19</a>]. (See <a href=\"topic.htm?path=management-of-the-short-bowel-syndrome-in-adults#H111555138\" class=\"medical medical_review\">&quot;Management of the short bowel syndrome in adults&quot;, section on 'Pharmacologic therapy to reduce fluid loss'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Diabetes mellitus</strong> &ndash; Synthetic glucagon-like peptide (GLP)-1-based therapies (eg, GLP-1 receptor agonists [eg, <a href=\"topic.htm?path=exenatide-drug-information\" class=\"drug drug_general\">exenatide</a>, <a href=\"topic.htm?path=liraglutide-drug-information\" class=\"drug drug_general\">liraglutide</a>] and dipeptidyl peptidase 4 [DPP-4] inhibitors) are used to treat diabetes mellitus. GI hormones that possess incretin activity (eg, glucose-dependent insulinotropic peptide [GIP] and GLP-1) are potentially useful for treatment of diabetes mellitus [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/20\" class=\"abstract_t\">20</a>]. However, GLP-1 exhibits a short half-life of one to two minutes due to N-terminal degradation by the enzyme DPP-4. GLP-1-agonists (eg, exenatide, liraglutide) are more resistant to degradation by DPP-4. DPP-4 inhibitors (eg, <a href=\"topic.htm?path=sitagliptin-drug-information\" class=\"drug drug_general\">sitagliptin</a>) inhibit the degradation of both GIP and GLP-1. GLP-1-based therapies affect glucose control through several mechanisms, including enhancement of glucose-dependent insulin secretion, slowed gastric emptying, and reduction of postprandial glucagon and of food intake [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-mellitus\" class=\"medical medical_review\">&quot;Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus&quot;</a> and <a href=\"topic.htm?path=dipeptidyl-peptidase-4-dpp-4-inhibitors-for-the-treatment-of-type-2-diabetes-mellitus\" class=\"medical medical_review\">&quot;Dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Gastrointestinal tract bleeding</strong> &ndash; <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">Octreotide</a> is used in the treatment of variceal bleeding and may also reduce the risk of GI bleeding due to nonvariceal causes [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/22\" class=\"abstract_t\">22</a>]. Octreotide is not recommended for routine use in patients with acute nonvariceal upper GI bleeding. Its role is generally limited to settings in which endoscopy is unavailable or as a means to help stabilize patients before definitive therapy can be performed. (See <a href=\"topic.htm?path=methods-to-achieve-hemostasis-in-patients-with-acute-variceal-hemorrhage#H62477672\" class=\"medical medical_review\">&quot;Methods to achieve hemostasis in patients with acute variceal hemorrhage&quot;, section on 'Somatostatin and its analogs'</a> and <a href=\"topic.htm?path=approach-to-acute-upper-gastrointestinal-bleeding-in-adults#H9942856\" class=\"medical medical_review\">&quot;Approach to acute upper gastrointestinal bleeding in adults&quot;, section on 'Vasoactive medications'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2462365107\"><span class=\"h2\">Other investigational uses</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Obesity</strong> &ndash; Several GI peptides result in weight loss, either by a reduction in food intake or by increasing energy expenditure. Investigational GI peptide-based drugs for weight loss include small molecule CCK receptor agonists peptide YY (PYY) analogues (eg, PYY[3-36]), oxyntomodulin, amylin, and ghrelin [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/23\" class=\"abstract_t\">23</a>]. (See <a href=\"topic.htm?path=physiology-of-cholecystokinin\" class=\"medical medical_review\">&quot;Physiology of cholecystokinin&quot;</a> and <a href=\"topic.htm?path=pancreatic-polypeptide-peptide-yy-and-neuropeptide-y\" class=\"medical medical_review\">&quot;Pancreatic polypeptide, peptide YY, and neuropeptide Y&quot;</a> and <a href=\"topic.htm?path=ghrelin\" class=\"medical medical_review\">&quot;Ghrelin&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Crohn disease</strong> &ndash; Antisense oligonucleotides are nucleic acid sequences that bind to RNA or DNA with a high degree of specificity, and can thereby block expression of a specific protein [<a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/24-26\" class=\"abstract_t\">24-26</a>]. Mongersen, an oral SMAD7 antisense oligonucleotide, is being evaluated for treatment of Crohn disease. (See <a href=\"topic.htm?path=investigational-therapies-in-the-medical-management-of-crohn-disease\" class=\"medical medical_review\">&quot;Investigational therapies in the medical management of Crohn disease&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H365248287\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gastrointestinal (GI) peptides are involved in GI motility, secretion, absorption, growth, and development. GI peptides are classified according to their primary structure (<a href=\"image.htm?imageKey=GAST%2F52723\" class=\"graphic graphic_table graphicRef52723 \">table 1</a>). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H2873712916\" class=\"local\">'Classification'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>GI peptides are produced by enteroendocrine cells that are dispersed throughout the GI tract. However, specific types of cells demonstrate regional specificity (<a href=\"image.htm?imageKey=GAST%2F65917\" class=\"graphic graphic_table graphicRef65917 \">table 2</a>). This specificity may be related to the physiologic action of the peptide and receptor location. (See <a href=\"#H579955665\" class=\"local\">'Secretion'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All GI peptides are synthesized via gene transcription of DNA into messenger RNA (mRNA) and subsequently undergo translation into precursor proteins known as preprohormones. Subsequently, preprohormones are modified by posttranslational processing into various peptide cleavage products that are eventually secreted. Posttranslational modification of peptide hormones is important in receptor binding, signal transduction, and consequent cell responses, all of which may affect biological activity. (See <a href=\"#H380218849\" class=\"local\">'Posttranslational processing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When enteroendocrine cells are stimulated, peptides are secreted into the paracellular space. From the paracellular space, GI peptides can act on the same cells from which they are released (autocrine), neighboring cells (paracrine), on distant cells via the blood (endocrine), on cells following their release from nerves (neurocrine), or on adjacent nerves through a synaptic connection (<a href=\"image.htm?imageKey=GAST%2F77856\" class=\"graphic graphic_figure graphicRef77856 \">figure 3</a>). Negative feedback mechanisms avoid excess production and secretion of GI peptides. (See <a href=\"#H579955665\" class=\"local\">'Secretion'</a> above and <a href=\"#H1498382458\" class=\"local\">'Regulation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alterations in either GI peptide secretion or action can have deleterious effects. Clinically significant disease can occur due to overproduction by GI tumors (eg, gastrinoma, VIPoma), loss of regulation (eg, medication-induced hypersecretion), and receptor signaling errors (eg, toxin-induced diarrhea). (See <a href=\"#H2901161075\" class=\"local\">'Associated diseases'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Several GI peptides or their analogues or drugs targeted at specific GI hormone receptors have diagnostic and therapeutic uses (<a href=\"image.htm?imageKey=GAST%2F68963\" class=\"graphic graphic_table graphicRef68963 \">table 5</a>). As an example, the somatostatin analogue, <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> has been used for the treatment of endocrine tumors, chronic diarrhea, variceal hemorrhage, GI hormone-secreting tumors, and GI tumor diagnostic testing (somatostatin receptor scintigraphy). (See <a href=\"#H2\" class=\"local\">'Clinical application'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Gut Peptides, Walsh JH, Dockray GJ (Eds), Raven Press, New York 1994.</li><li class=\"breakAll\">Physiology of the Gastrointestinal Tract, 4th ed, Johnson LR (Ed), Elsevier Academic Press, New York 2006.</li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/3\" class=\"nounderline abstract_t\">Solcia E, Fiocca R, Rindi G, et al. The pathology of the gastrointestinal endocrine system. Endocrinol Metab Clin North Am 1993; 22:795.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/4\" class=\"nounderline abstract_t\">Frank J. How the ribosome works. Am Sci 1998; 86:428.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/5\" class=\"nounderline abstract_t\">Wilson KS, Noller HF. Molecular movement inside the translational engine. Cell 1998; 92:337.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/6\" class=\"nounderline abstract_t\">Rothman JE, Orci L. Budding vesicles in living cells. Sci Am 1996; 274:70.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/7\" class=\"nounderline abstract_t\">Rehfeld JF. Processing of precursors of gastroenteropancreatic hormones: diagnostic significance. J Mol Med (Berl) 1998; 76:338.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/8\" class=\"nounderline abstract_t\">Boh&oacute;rquez DV, Shahid RA, Erdmann A, et al. Neuroepithelial circuit formed by innervation of sensory enteroendocrine cells. J Clin Invest 2015; 125:782.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/9\" class=\"nounderline abstract_t\">Chandra R, Samsa LA, Vigna SR, Liddle RA. Pseudopod-like basal cell processes in intestinal cholecystokinin cells. Cell Tissue Res 2010; 341:289.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/10\" class=\"nounderline abstract_t\">Boh&oacute;rquez DV, Chandra R, Samsa LA, et al. Characterization of basal pseudopod-like processes in ileal and colonic PYY cells. J Mol Histol 2011; 42:3.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/11\" class=\"nounderline abstract_t\">Boh&oacute;rquez DV, Samsa LA, Roholt A, et al. An enteroendocrine cell-enteric glia connection revealed by 3D electron microscopy. PLoS One 2014; 9:e89881.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/12\" class=\"nounderline abstract_t\">Wang J, Cortina G, Wu SV, et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N Engl J Med 2006; 355:270.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/13\" class=\"nounderline abstract_t\">Longnecker DS. Hormones and receptors in gastrointestinal malignancies. Digestion 1990; 46 Suppl 2:92.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/14\" class=\"nounderline abstract_t\">Gill DM, Woolkalis MJ. Cholera toxin-catalyzed [32P]ADP-ribosylation of proteins. Methods Enzymol 1991; 195:267.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/15\" class=\"nounderline abstract_t\">Redfern JS, O'Dorisio TM. Therapeutic uses of gastrointestinal peptides. Endocrinol Metab Clin North Am 1993; 22:845.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/16\" class=\"nounderline abstract_t\">Strader AD, Woods SC. Gastrointestinal hormones and food intake. Gastroenterology 2005; 128:175.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/17\" class=\"nounderline abstract_t\">Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol 2005; 184:291.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/18\" class=\"nounderline abstract_t\">Yazbeck R. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome. Curr Opin Mol Ther 2010; 12:798.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/19\" class=\"nounderline abstract_t\">O'Keefe SJ, Jeppesen PB, Gilroy R, et al. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol 2013; 11:815.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/20\" class=\"nounderline abstract_t\">Nauck MA. Unraveling the science of incretin biology. Am J Med 2009; 122:S3.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/21\" class=\"nounderline abstract_t\">Brubaker PL. Incretin-based therapies: mimetics versus protease inhibitors. Trends Endocrinol Metab 2007; 18:240.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/22\" class=\"nounderline abstract_t\">Imperiale TF, Birgisson S. Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Ann Intern Med 1997; 127:1062.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/23\" class=\"nounderline abstract_t\">Karra E, Batterham RL. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol 2010; 316:120.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/24\" class=\"nounderline abstract_t\">Branch AD. A good antisense molecule is hard to find. Trends Biochem Sci 1998; 23:45.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/25\" class=\"nounderline abstract_t\">Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 1996; 36:107.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-gastrointestinal-peptides-in-health-and-disease/abstract/26\" class=\"nounderline abstract_t\">Bennett CF. Antisense oligonucleotides: is the glass half full or half empty? Biochem Pharmacol 1998; 55:9.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2534 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H365248287\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2873712916\" id=\"outline-link-H2873712916\">CLASSIFICATION</a></li><li><a href=\"#H2743601118\" id=\"outline-link-H2743601118\">SYNTHESIS AND SECRETION</a><ul><li><a href=\"#H936182783\" id=\"outline-link-H936182783\">Synthesis</a></li><li><a href=\"#H380218849\" id=\"outline-link-H380218849\">Posttranslational processing</a></li><li><a href=\"#H579955665\" id=\"outline-link-H579955665\">Secretion</a></li></ul></li><li><a href=\"#H1498382458\" id=\"outline-link-H1498382458\">REGULATION</a></li><li><a href=\"#H2901161075\" id=\"outline-link-H2901161075\">ASSOCIATED DISEASES</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLINICAL APPLICATION</a><ul><li><a href=\"#H1233968111\" id=\"outline-link-H1233968111\">Diagnostic evaluation</a></li><li><a href=\"#H4096102322\" id=\"outline-link-H4096102322\">Therapeutic uses</a></li><li><a href=\"#H2462365107\" id=\"outline-link-H2462365107\">Other investigational uses</a></li></ul></li><li><a href=\"#H365248287\" id=\"outline-link-H365248287\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/2534|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/50859\" class=\"graphic graphic_figure\">- Peptide hormone synthesis</a></li><li><a href=\"image.htm?imageKey=GAST/58292\" class=\"graphic graphic_figure\">- Posttranslantional processing</a></li><li><a href=\"image.htm?imageKey=GAST/77856\" class=\"graphic graphic_figure\">- GI peptide regulation of cell function</a></li></ul></li><li><div id=\"GAST/2534|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/52723\" class=\"graphic graphic_table\">- GI peptide families</a></li><li><a href=\"image.htm?imageKey=GAST/65917\" class=\"graphic graphic_table\">- Gastroenteropancreatic endocrine cells</a></li><li><a href=\"image.htm?imageKey=GAST/64495\" class=\"graphic graphic_table\">- GI peptide modes of action</a></li><li><a href=\"image.htm?imageKey=GAST/71093\" class=\"graphic graphic_table\">- Sx GI endocrine neoplasms</a></li><li><a href=\"image.htm?imageKey=GAST/68963\" class=\"graphic graphic_table\">- Gastrointestinal peptides used in clinical practice</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-acute-upper-gastrointestinal-bleeding-in-adults\" class=\"medical medical_review\">Approach to acute upper gastrointestinal bleeding in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cholera-clinical-features-diagnosis-treatment-and-prevention\" class=\"medical medical_review\">Cholera: Clinical features, diagnosis, treatment, and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dipeptidyl-peptidase-4-dpp-4-inhibitors-for-the-treatment-of-type-2-diabetes-mellitus\" class=\"medical medical_review\">Dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ghrelin\" class=\"medical medical_review\">Ghrelin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-mellitus\" class=\"medical medical_review\">Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=insulin-action\" class=\"medical medical_review\">Insulin action</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=investigational-therapies-in-the-medical-management-of-crohn-disease\" class=\"medical medical_review\">Investigational therapies in the medical management of Crohn disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-the-short-bowel-syndrome-in-adults\" class=\"medical medical_review\">Management of the short bowel syndrome in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methods-to-achieve-hemostasis-in-patients-with-acute-variceal-hemorrhage\" class=\"medical medical_review\">Methods to achieve hemostasis in patients with acute variceal hemorrhage</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pancreatic-polypeptide-peptide-yy-and-neuropeptide-y\" class=\"medical medical_review\">Pancreatic polypeptide, peptide YY, and neuropeptide Y</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=peptide-hormone-signal-transduction-and-regulation\" class=\"medical medical_review\">Peptide hormone signal transduction and regulation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=physiology-of-cholecystokinin\" class=\"medical medical_review\">Physiology of cholecystokinin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=physiology-of-gastrin\" class=\"medical medical_review\">Physiology of gastrin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=physiology-of-somatostatin-and-its-analogues\" class=\"medical medical_review\">Physiology of somatostatin and its analogues</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=secretin\" class=\"medical medical_review\">Secretin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis</a></li></ul></div></div>","javascript":null}